A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2017 According to a Corbus Pharmaceuticals media release, data from this study was presented at the European Cystic Fibrosis Society ("ECFS") conference in June 2017 and was also recently presented at the North American Cystic Fibrosis Conference ("NACFC").
    • 25 Sep 2017 According to a Corbus Pharmaceuticals media release, data will be presented at the 2017 North American Cystic Fibrosis Conference (NACFC).
    • 09 May 2017 According to a Corbus Pharmaceuticals media release, results from this trial will be presented at the European Cystic Fibrosis (ECFS) conference in June 2017 and the North American Cystic Fibrosis Conference (NACFC) in November 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top